Northwest Biotherapeutics (NWBO) Ratios
Northwest Biotherapeutics Ratios
NWBO's free cash flow for Q2 2026 was $-7.04M. For the 2026 fiscal year, NWBO's free cash flow was increased by $129.00K and operating cash flow was $-7.17M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.06 | 0.06 | 0.09 | 0.07 | 0.13 |
| Quick Ratio | 0.06 | 0.06 | 0.09 | 0.07 | 0.13 |
| Cash Ratio | 0.03 | 0.03 | 0.05 | 0.06 | 0.11 |
| Solvency Ratio | -0.46 | -0.77 | -0.81 | -0.65 | 1.09 |
| Operating Cash Flow Ratio | -0.49 | -0.84 | -1.19 | -0.42 | -0.29 |
| Short-Term Operating Cash Flow Coverage | -1.06 | -1.66 | -2.62 | -3.32 | -5.07 |
| Net Current Asset Value | $ -123.34M | $ -101.65M | $ -70.80M | $ -150.00M | $ -146.86M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.80 | 2.52 | 1.64 | 0.85 | 0.95 |
| Debt-to-Equity Ratio | -1.36 | -0.85 | -0.97 | -0.21 | -0.31 |
| Debt-to-Capital Ratio | 3.76 | -5.84 | -32.18 | -0.26 | -0.45 |
| Long-Term Debt-to-Capital Ratio | -0.60 | -0.56 | -0.76 | -0.05 | -0.25 |
| Financial Leverage Ratio | -1.71 | -0.34 | -0.59 | -0.24 | -0.32 |
| Debt Service Coverage Ratio | -1.51 | -1.75 | -2.15 | -4.44 | 14.70 |
| Interest Coverage Ratio | 6.89 | -8.56 | -10.59 | -11.07 | -10.52 |
| Debt to Market Cap | 0.18 | 0.19 | 0.05 | 0.03 | 0.05 |
| Interest Debt Per Share | 0.04 | 0.06 | 0.05 | 0.03 | 0.05 |
| Net Debt to EBITDA | -1.24 | -0.89 | -0.78 | -0.20 | 0.12 |
| Profitability Margins | |||||
| Gross Profit Margin | -69.59% | 100.00% | -1335.30% | 8.02% | -1920.70% |
| EBIT Margin | -3773.88% | -5476.41% | -2954.04% | -5880.21% | 18322.09% |
| EBITDA Margin | -3604.28% | -5328.51% | -2864.34% | -5788.24% | 18380.40% |
| Operating Profit Margin | -4347.90% | -4812.45% | -2873.08% | -3991.74% | -5243.98% |
| Pretax Profit Margin | -4404.86% | -6062.08% | -3240.11% | -6240.76% | 17823.48% |
| Net Profit Margin | -4461.32% | -6062.08% | -3240.11% | -6240.76% | 17823.48% |
| Continuous Operations Profit Margin | -4461.32% | -6062.08% | -3240.11% | -6240.76% | 17823.48% |
| Net Income Per EBT | 101.28% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 101.31% | 125.97% | 112.77% | 156.34% | -339.88% |
| Return on Assets (ROA) | -75.63% | -313.45% | -224.65% | -335.32% | 446.03% |
| Return on Equity (ROE) | 129.23% | 106.07% | 133.26% | 81.99% | -144.47% |
| Return on Capital Employed (ROCE) | 575.54% | 160.08% | 320.13% | 70.95% | 56.30% |
| Return on Invested Capital (ROIC) | -186.49% | 972.34% | -1606.60% | 85.65% | 61.47% |
| Return on Tangible Assets | -223.75% | -337.68% | -241.26% | -357.19% | 468.40% |
| Earnings Yield | -18.55% | -24.98% | -7.93% | -13.18% | 29.29% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.43 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.08 | 0.11 | 2.01 | 0.09 | 1.86 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.06 | 0.07 | 0.09 | 0.09 | 0.05 |
| Asset Turnover | 0.02 | 0.05 | 0.07 | 0.05 | 0.03 |
| Working Capital Turnover Ratio | -0.02 | -0.03 | -0.02 | -0.01 | -0.00 |
| Cash Conversion Cycle | -4730.56 | -3332.32 | -181.49 | -4159.77 | -196.75 |
| Days of Sales Outstanding | 82.38 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 4812.94 | 3332.32 | 181.49 | 4159.77 | 196.75 |
| Operating Cycle | 82.38 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.03 | -0.05 | -0.05 | -0.05 | -0.04 |
| Free Cash Flow Per Share | -0.03 | -0.05 | -0.05 | -0.05 | -0.05 |
| Dividend Paid and CapEx Coverage Ratio | -29.76 | -56.23 | -15.61 | -18.19 | -6.37 |
| Capital Expenditure Coverage Ratio | -29.76 | -56.23 | -15.61 | -18.19 | -6.37 |
| Operating Cash Flow Coverage Ratio | -0.69 | -0.85 | -1.18 | -1.98 | -1.00 |
| Operating Cash Flow to Sales Ratio | -32.48 | -41.26 | -27.76 | -31.36 | -38.11 |
| Free Cash Flow Yield | -13.96% | -17.30% | -7.23% | -6.99% | -7.25% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.39 | -3.94 | -12.61 | -7.59 | 3.41 |
| Price-to-Sales (P/S) Ratio | 240.49 | 242.69 | 408.63 | 473.52 | 608.42 |
| Price-to-Book (P/B) Ratio | -6.97 | -4.25 | -16.81 | -6.22 | -4.93 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.16 | -5.78 | -13.83 | -14.31 | -13.80 |
| Price-to-Operating Cash Flow Ratio | -7.40 | -5.88 | -14.72 | -15.10 | -15.97 |
| Price-to-Earnings Growth (PEG) Ratio | 0.14 | -0.20 | 0.30 | 0.05 | -0.03 |
| Enterprise Value Multiple | -7.92 | -5.44 | -15.05 | -8.38 | 3.44 |
| Enterprise Value | 393.18M | 400.67M | 832.91M | 816.58M | 634.55M |
| EV to EBITDA | -7.92 | -5.44 | -15.05 | -8.38 | 3.44 |
| EV to Sales | 285.32 | 289.92 | 431.11 | 485.19 | 631.39 |
| EV to Free Cash Flow | -8.50 | -6.90 | -14.59 | -14.67 | -14.32 |
| EV to Operating Cash Flow | -8.78 | -7.03 | -15.53 | -15.47 | -16.57 |
| Tangible Book Value Per Share | -0.07 | -0.07 | -0.04 | -0.13 | -0.14 |
| Shareholders’ Equity Per Share | -0.03 | -0.06 | -0.04 | -0.13 | -0.14 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.04 | -0.07 | -0.06 | -0.10 | 0.21 |
| Tax Burden | 1.01 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.17 | 1.11 | 1.10 | 1.06 | 0.97 |
| Research & Development to Revenue | 20.89 | 25.24 | 14.35 | 21.10 | 20.21 |
| SG&A to Revenue | 23.59 | 23.88 | 15.38 | 19.82 | 33.23 |
| Stock-Based Compensation to Revenue | 0.88 | 2.50 | 2.28 | 7.31 | 15.42 |
| Income Quality | 0.74 | 0.68 | 0.86 | 0.50 | -0.21 |
Currency in USD